Aktuelle Incyte Tafasitamab Daten demonstrieren auf dem ASH 2024 deutlich verbessertes progressionsfreies berleben bei Patienten mit rezidiviertem oder refraktrem follikulrem Lymphom
| FTDZX Fund | USD 128.82 0.40 0.31% |
Slightly above 56% of Franklin Biotechnology's investor base is looking to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are alarmed at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
Incyte gab heute weitere Ergebnisse der bewertenden Behandlung der inMIND-Phase-III-Schlsselstudie mit Tafasitamab , einem h
Read at businesswire.com
 |
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Position Weight
Cash Position Weight Comparative Analysis
Franklin Biotechnology is currently under evaluation in cash position weight among similar funds. Percentage of fund asset invested in cash equivalents or risk-free instruments. About 40% of all global funds carry cash on their balance sheet.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| MFTFX | Arrow Managed | 1.05 | ||||
| ALNVX | Ab New | 0.11 | ||||
| HDCAX | Rational Dividend | 0.10 | ||||
| OPTCX | Rbb Fund | 0.20 | ||||
| LMUSX | Qs Us | 0.80 | ||||
| ADGAX | Ab E | 0.93 | ||||
| MSSGX | Small Pany | 3.85 |
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |